DiaMedica Inc. Appoints Dr. Ralph A. DeFronzo to its Scientific Advisory Board
03 6월 2014 - 11:56PM
Marketwired
DiaMedica Inc. Appoints Dr. Ralph A. DeFronzo to its Scientific
Advisory Board
MINNEAPOLIS, MINNESOTA--(Marketwired - Jun 3, 2014) - DiaMedica
Inc. ("DiaMedica") (TSX-VENTURE:DMA), a clinical stage
biopharmaceutical company focused on the treatment of diabetes and
its complications, announced today the appointment of Ralph A.
DeFronzo, MD, to the Company's Scientific Advisory Board. Dr.
DeFronzo, is a Professor of Medicine, the Chief of the Diabetes
Division at the University of Texas Health Science Center, and the
Deputy Director of the Texas Diabetes Institute, San Antonio,
Texas.
With more than 650
articles published in peer-reviewed medical journals, Dr. DeFronzo
is a distinguished diabetes researcher, clinician, and teacher, and
is a recipient of several prestigious national and international
awards. In 2008, Dr. DeFronzo received the Banting Award from the
American Diabetes Association (ADA) and the Claude Bernard Award
from the European Association for the Study of Diabetes (EASD).
These represent the highest scientific achievement awards given by
the American and European Diabetes Associations, respectively. In
2008, Dr. DeFronzo also received the Italian Diabetes Mentor Prize
and the Philip Bondy Lectureship at Yale University. He also is the
recipient of the ADA's Albert Renold Award (2002) for lifetime
commitment to the training of young diabetes investigators. For his
work in this area, Dr. DeFronzo received the prestigious Lilly
Award (1987) from the ADA, the Banting Lectureship (1988) from the
Canadian Diabetes Association, and the Novartis Award (2003) for
outstanding clinical investigation worldwide. Dr. DeFronzo has
served as an Advisory Board member for several pharmaceutical
companies and has delivered numerous keynote speeches at major
national and international conferences on diabetes and its
complications.
"Dr. DeFronzo is a
world-renowned researcher, clinician, and educator in the diabetes
field. We are honored and delighted to have him join DiaMedica's
Scientific Advisory Board," said Rick Pauls, DiaMedica's President
and CEO. "We intend to leverage Dr. DeFronzo's vast knowledge on
the subject of diabetes and kidney disease, and his reputable
standing with numerous international diabetes organizations, as we
move forward with our products."
Dr. DeFronzo
commented, "It is a pleasure to join DiaMedica's distinguished
Scientific Advisory Board. I am eager to begin working with the
Company and to share my expertise with the team to develop
innovative approaches for treating diabetes and related
complications."
Dr. DeFronzo is a
graduate of Yale University (BS) and Harvard Medical School (MD)
and completed his training in Internal Medicine at the Johns
Hopkins Hospital. He completed fellowships in Endocrinology at the
National Institutes of Health and Baltimore City Hospitals and in
Nephrology at the Hospital of the University of Pennsylvania. His
major interests focus on the pathogenesis and treatment of type 2
diabetes mellitus and the central role of insulin resistance in the
metabolic-cardiovascular cluster of disorders known collectively as
the Insulin Resistance Syndrome. Using the euglycemic insulin clamp
technique in combination with radioisotope turnover methodology,
limb catheterization, indirect calorimetry, and muscle biopsy, he
has helped to define the biochemical and molecular disturbances
responsible for insulin resistance in type 2 diabetes mellitus.
About DiaMedica
DiaMedica is a
publicly traded (TSX-VENTURE:DMA) clinical stage biopharmaceutical
company focused on the discovery and development of novel therapies
to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage product, DM199, is a recombinant
human protein known as rhKLK1 that represents a novel approach to
treating diabetes and associated complications. DiaMedica is also
developing DM204, a preclinical-stage monoclonal antibody for the
treatment of Type 2 diabetes.
DiaMedica's common
shares are listed on the TSX Venture Exchange in Canada under the
trading symbol 'DMA'.
FORWARD-LOOKING
STATEMENTS
The statements made
in this press release that are not historical facts contain forward
- looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which
address DiaMedica's expectations, including the intended use of the
net proceeds of the Offering, should be considered forward-looking
statements. Such statements are based on management's exercise of
business judgment as well as assumptions made by and information
currently available to management. When used in this document, the
words "may", "will", "anticipate", "believe", "estimate", "expect",
"intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on
these forward- looking statements. These statements reflect a
current view of future events and are subject to certain risks and
uncertainties as contained in DiaMedica's filings with Canadian
securities regulatory authorities. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially
from those anticipated in these forward-looking statements.
DiaMedica undertakes no obligation, and does not intend, to update,
revise or otherwise publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof, or to reflect the occurrence of any unanticipated
events, unless required by law. Although management believes that
expectations are based on reasonable assumptions, no assurance can
be given that these expectations will materialize.
Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this
press release.
DiaMedica Inc.John SavageChief Financial Officer(763)
270-0603info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024